Technical Analysis for BNTC - Benitec Biopharma Limited

Grade Last Price % Change Price Change
grade C 1.95 -2.50% -0.05
BNTC closed down 2.5 percent on Friday, March 22, 2019, on 1 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical BNTC trend table...

Date Alert Name Type % Chg
Mar 22 Narrow Range Bar Range Contraction 0.00%
Mar 22 Gapped Down Weakness 0.00%
Mar 21 Shooting Star Candlestick Bearish -2.50%
Mar 21 Narrow Range Bar Range Contraction -2.50%
Mar 21 Doji - Bearish? Reversal -2.50%
Mar 21 Wide Bands Range Expansion -2.50%
Mar 21 Gapped Up Strength -2.50%
Mar 21 Up 3 Days in a Row Strength -2.50%
Mar 21 Up 4 Days in a Row Strength -2.50%
Mar 20 20 DMA Support Bullish -1.52%

Older signals for BNTC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Biotechnology Biopharmaceutical Biology Pain Chemotherapy Genetics Gene Expression Genetic Engineering Wet Age Related Macular Degeneration Hiv/Aids Hepatitis B Huntington's Disease Hepatitis C Retinitis Pigmentosa RNA Oculopharyngeal Muscular Dystrophy Clinical Applications Chronic And Life Threatening Conditions
Is BNTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.9
52 Week Low 1.01
Average Volume 7,624
200-Day Moving Average 2.2321
50-Day Moving Average 1.6715
20-Day Moving Average 1.9154
10-Day Moving Average 1.9384
Average True Range 0.1375
ADX 28.87
+DI 30.13
-DI 25.7982
Chandelier Exit (Long, 3 ATRs ) 1.8574
Chandelier Exit (Short, 3 ATRs ) 1.9599
Upper Bollinger Band 2.1902
Lower Bollinger Band 1.6406
Percent B (%b) 0.56
BandWidth 28.693745
MACD Line 0.0721
MACD Signal Line 0.0815
MACD Histogram -0.0094
Fundamentals Value
Market Cap 20 Million
Num Shares 10.3 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -3.75
Price-to-Sales 3.15
Price-to-Book 1.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.95
Resistance 3 (R3) 1.95 1.95 1.95
Resistance 2 (R2) 1.95 1.95 1.95 1.95
Resistance 1 (R1) 1.95 1.95 1.95 1.95 1.95
Pivot Point 1.95 1.95 1.95 1.95 1.95
Support 1 (S1) 1.95 1.95 1.95 1.95 1.95
Support 2 (S2) 1.95 1.95 1.95 1.95
Support 3 (S3) 1.95 1.95 1.95
Support 4 (S4) 1.95